CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $181.43M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 2.43: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
181.43MUSDvs all stocks (USD)
Revenue (TTM)
457.45MUSDvs all stocks (USD)
Profit Margin
-18.40%Beta
1.29xvs all stocks
52-Week Change
-66.90%vs all stocks
Market Capitalization
181.43MUSDvs all stocks (USD)
Enterprise Value
342.15MUSDvs all stocks (USD)
Forward P/E
-4.55xPrice to Sales (TTM)
0.3966xPrice to Book (MRQ)
1.22xEnterprise to Revenue
0.7480xEnterprise to EBITDA
-35.27xGross Margin
44.70%Profit Margin
-18.40%Operating Margin
-119.25%Return on Assets (TTM)
-4.11%Return on Equity (TTM)
-25.92%Revenue (TTM)
457.45MUSDvs all stocks (USD)
Revenue per Share (TTM)
3.59USDUpdated Sep 28, 2026Quarterly Revenue Growth
-56.70%Gross Profit (TTM)
327.02MUSDvs all stocks (USD)
EBITDA (TTM)
93.98MUSDvs all stocks (USD)
Net Income (TTM)
-101.68MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-57.53%Operating Cash Flow (TTM)
31.97MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
28.45MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
563.03MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
137.52MUSDFY2025 · Dec 31, 2025Gross Profit
425.51MUSDFY2025 · Dec 31, 2025Operating Income
55.87MUSDvs all stocks (USD)
Pre-tax Income
46.97MUSDFY2025 · Dec 31, 2025Income Tax Expense
9.94MUSDFY2025 · Dec 31, 2025Net Income
37.03MUSDFY2025 · Dec 31, 2025EBIT
55.87MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
93.98MUSDFY2025 · Dec 31, 2025Research & Development
44.54MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
326.24MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-1.14MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.28MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.1600USDFY2025 · Dec 31, 2025EPS (Diluted)
0.1500USDFY2025 · Dec 31, 2025Basic Shares Outstanding
126.74MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
126.74MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
37.03MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
6.18MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-40.08MUSDFY2025 · Dec 31, 2025Free Cash Flow
-54.23MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
94.33MUSDFY2025 · Dec 31, 2025Income Tax Paid
5.35MUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
37.03MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
26.94MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
9.50MUSDFY2025 · Dec 31, 2025Stock-based Compensation
13.30MUSDFY2025 · Dec 31, 2025Other Non-cash Items
15.73MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-115.80MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-528.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-26.25MUSDFY2025 · Dec 31, 2025Capital Expenditures
-14.15MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-14.15MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.17MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-16.35MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-17.52MUSDFY2025 · Dec 31, 2025Shares Outstanding
128.67MSharesUpdated Sep 28, 2026Float Shares
61.06MSharesUpdated Sep 28, 2026Shares Short
14.12MSharesUpdated Sep 28, 2026Short Ratio
20.97daysvs all stocks
Short % of Shares Outstanding
17.26%vs all stocks
% Held by Insiders
47.46%vs all stocks
% Held by Institutions
51.70%vs all stocks
Total Cash (MRQ)
46.10MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.3580USDUpdated Sep 28, 2026Total Debt (MRQ)
66.95MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.2324xCurrent Ratio (MRQ)
3.52xBook Value per Share (MRQ)
1.15USDUpdated Sep 28, 2026Total Assets
598.73MUSDvs all stocks (USD)
Total Current Assets
362.19MUSDFY2025 · Dec 31, 2025Total Liabilities
164.81MUSDFY2025 · Dec 31, 2025Total Non-current Assets
236.54MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
64.69MUSDFY2025 · Dec 31, 2025Total Current Liabilities
100.12MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
93.68MUSDFY2025 · Dec 31, 2025Accounts Receivable
217.45MUSDFY2025 · Dec 31, 2025Inventory
29.63MUSDFY2025 · Dec 31, 2025Accounts Payable
31.95MUSDFY2025 · Dec 31, 2025Short-term Debt
18.64MUSDFY2025 · Dec 31, 2025Deferred Revenue
3.86MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.26MUSDFY2025 · Dec 31, 2025Long-term Debt
63.49MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.19MUSDFY2025 · Dec 31, 2025Common Stock (Book)
13.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-3.08MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
433.92MUSDvs all stocks (USD)
52-Week Low
1.34USDUpdated Sep 28, 202652-Week High
7.08USDUpdated Sep 28, 202652-Week Change
-66.90%vs all stocks
Beta
1.29xvs all stocks
50-Day MA
1.92USDUpdated Sep 28, 2026200-Day MA
2.86USDUpdated Sep 28, 2026Avg 10-Day Volume
586.38KSharesUpdated Sep 28, 2026Avg 30-Day Volume
648.64KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.7900USDUpdated Sep 28, 2026Other Income / Expense
-11.18MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.45Profit Margin: -0.18
Financial Health
Altman Z-Score 2.43: grey zoneSignificant
Altman Z-Score: 2.43
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $181.43M, lower than 95% of all stocks globallySignificant
Market cap (USD): 181,431,112Global P5: 275,556,405.438
Levered free cash flow is $28.45M, above the global median of $18.73MNotable
Levered free cash flow (USD): 28,450,000Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Alx Oncology Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
MediWound Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Cabio Biotech Wuhan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
NervGen Pharma Corp.
Tier 1ProductionApproval-Gated PipelineRule
Intocell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hans Biomed Corp.
Tier 1ProductionApproval-Gated PipelineRule
Coherus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anika Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Rightongene Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tonix Pharmaceuticals Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk